Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?

Our assessment of cancer immunotherapies (CIT) randomized controlled trials (RCTs) published over the last two years in major journals (Appendix 2) reveals that knowledge of toxicities is still hindered by practices in the reporting and analysis of safety data.